HUM-MOLGEN events: Biomarker Discovery from Gene Expression: Challenges and Solutions for Success

Who Should Attend?

This webinar will appeal to pharmaceutical companies and biotechnology companies and is relevant to both oncology and non-oncology indication focus. This webinar will benefit senior biopharma decision makers with responsibilities including, but not limited to:

Data Sciences

Biomarker Discovery

Translational Medicine

Clinical Development

CDx Development

What You Will Learn

What you will learn:

Challenges associated with analysing gene expression data

Key study design considerations for biomarker discovery

Best practices for training and validating a gene expression signature

Making use of public data repositories and integrating different data types

Innovative reporting of gene expression signatures using Almac’s proprietary bioinformatics software solution – claraT

Speaker

http://Dr.%20Laura%20Knight,%20Almac%20Diagnostic%20Services

Dr. Laura Knight, VP of Data Sciences, Almac Diagnostic Services

Dr. Laura Knight is VP of Data Sciences within Almac Diagnostic Services. In this role, she leads a department of bioinformatics scientists, statisticians, and software developers providing technology integration and benchmarking, and supporting Almac Diagnostics Services’ Clients in the discovery, development and validation of biomarkers for clinical trial and CDx assays. Laura has a breadth of experience in the biomarker field with a strong interest in the application of machine learning techniques to gene expression data for biomarker discovery. Prior to joining Almac in 2009, Laura studied at Queen’s University Belfast and received a first-class Honours degree in Mathematics and Theoretical Physics before completing her PhD in Mathematics and Statistics with applied Bioinformatics, also from Queen’s University Belfast, where she currently holds an Honorary Lectureship position.